Montelukast Loratadine

Malstrom K, Meltzer E, Prenner B, Lu S, Weinstein S, Wolfe J, Wei LX, Reiss TF. Effects of montelukast (a leukottiene receptor antagonist), loratadine, montelukast + loratadine and placebo in seasonal allergic rhinitis and conjunctivitis. J Allergy Clin Immunol (1998) 101, S97. 

Meltzer, E. O., Malmstrom, K., Lu, S., et al. (2000) Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis a randomized, placebo-controlled clinical trial. J. Allergy Clin. Immunol. 105, 917-922. 

Wilson AM, Orr LC, Coutie WJ, Sims ELI, Lipworth BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domicihary nasal peak flow and symptoms in seasonal allergic rhinitis. Qin Exp Allergy 2002 32(l) 126-32. 

Reicin A, White R, Weinstein SF, Finn AF Jr, Nguyen H, Peszek I, Geissler L, Seidenberg BC. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 2000 160(16) 2481-8. 

Montelukast does not interact to a clinically relevant extent with loratadine or terfenadine. 

Healthy subjects were given terfenadine 60 mg every 12 hours for 14 days, with montelukast 10 mg daily from day 8 to day 14. It was found that the terfenadine pharmacokinetics and the QTc interval were unaltered by concurrent use. No adverse interactions were seen in large numbers of patients given montelukast 10 or 20 mg and loratadine 10 mg, and the combination was found to be beneficial in the treatment of allergic rhinitis and conjunctivitis. No special precautions are therefore needed if these drugs are given concurrentiy. 

---